Immunoproteomics using polyclonal antibodies and stable isotope-labeled affinity-purified recombinant proteins. 2014

Fredrik Edfors, and Tove Boström, and Björn Forsström, and Marlis Zeiler, and Henrik Johansson, and Emma Lundberg, and Sophia Hober, and Janne Lehtiö, and Matthias Mann, and Mathias Uhlen
From the ‡Science for Life Laboratory, KTH - Royal Institute of Technology, SE-171 21 Stockholm, Sweden;

The combination of immuno-based methods and mass spectrometry detection has great potential in the field of quantitative proteomics. Here, we describe a new method (immuno-SILAC) for the absolute quantification of proteins in complex samples based on polyclonal antibodies and stable isotope-labeled recombinant protein fragments to allow affinity enrichment prior to mass spectrometry analysis and accurate quantification. We took advantage of the antibody resources publicly available from the Human Protein Atlas project covering more than 80% of all human protein-coding genes. Epitope mapping revealed that a majority of the polyclonal antibodies recognized multiple linear epitopes, and based on these results, a semi-automated method was developed for peptide enrichment using polyclonal antibodies immobilized on protein A-coated magnetic beads. A protocol based on the simultaneous multiplex capture of more than 40 protein targets showed that approximately half of the antibodies enriched at least one functional peptide detected in the subsequent mass spectrometry analysis. The approach was further developed to also generate quantitative data via the addition of heavy isotope-labeled recombinant protein fragment standards prior to trypsin digestion. Here, we show that we were able to use small amounts of antibodies (50 ng per target) in this manner for efficient multiplex analysis of quantitative levels of proteins in a human HeLa cell lysate. The results suggest that polyclonal antibodies generated via immunization of recombinant protein fragments could be used for the enrichment of target peptides to allow for rapid mass spectrometry analysis taking advantage of a substantial reduction in sample complexity. The possibility of building up a proteome-wide resource for immuno-SILAC assays based on publicly available antibody resources is discussed.

UI MeSH Term Description Entries
D007553 Isotope Labeling Techniques for labeling a substance with a stable or radioactive isotope. It is not used for articles involving labeled substances unless the methods of labeling are substantively discussed. Tracers that may be labeled include chemical substances, cells, or microorganisms. Isotope Labeling, Stable,Isotope-Coded Affinity Tagging,Isotopically-Coded Affinity Tagging,Affinity Tagging, Isotope-Coded,Affinity Tagging, Isotopically-Coded,Isotope Coded Affinity Tagging,Labeling, Isotope,Labeling, Stable Isotope,Stable Isotope Labeling,Tagging, Isotope-Coded Affinity,Tagging, Isotopically-Coded Affinity
D009363 Neoplasm Proteins Proteins whose abnormal expression (gain or loss) are associated with the development, growth, or progression of NEOPLASMS. Some neoplasm proteins are tumor antigens (ANTIGENS, NEOPLASM), i.e. they induce an immune reaction to their tumor. Many neoplasm proteins have been characterized and are used as tumor markers (BIOMARKERS, TUMOR) when they are detectable in cells and body fluids as monitors for the presence or growth of tumors. Abnormal expression of ONCOGENE PROTEINS is involved in neoplastic transformation, whereas the loss of expression of TUMOR SUPPRESSOR PROTEINS is involved with the loss of growth control and progression of the neoplasm. Proteins, Neoplasm
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D002853 Chromatography, Liquid Chromatographic techniques in which the mobile phase is a liquid. Liquid Chromatography
D006367 HeLa Cells The first continuously cultured human malignant CELL LINE, derived from the cervical carcinoma of Henrietta Lacks. These cells are used for, among other things, VIRUS CULTIVATION and PRECLINICAL DRUG EVALUATION assays. Cell, HeLa,Cells, HeLa,HeLa Cell
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000906 Antibodies Immunoglobulin molecules having a specific amino acid sequence by virtue of which they interact only with the ANTIGEN (or a very similar shape) that induced their synthesis in cells of the lymphoid series (especially PLASMA CELLS).
D000939 Epitopes Sites on an antigen that interact with specific antibodies. Antigenic Determinant,Antigenic Determinants,Antigenic Specificity,Epitope,Determinant, Antigenic,Determinants, Antigenic,Specificity, Antigenic
D013058 Mass Spectrometry An analytical method used in determining the identity of a chemical based on its mass using mass analyzers/mass spectrometers. Mass Spectroscopy,Spectrometry, Mass,Spectroscopy, Mass,Spectrum Analysis, Mass,Analysis, Mass Spectrum,Mass Spectrum Analysis,Analyses, Mass Spectrum,Mass Spectrum Analyses,Spectrum Analyses, Mass
D015972 Gene Expression Regulation, Neoplastic Any of the processes by which nuclear, cytoplasmic, or intercellular factors influence the differential control of gene action in neoplastic tissue. Neoplastic Gene Expression Regulation,Regulation of Gene Expression, Neoplastic,Regulation, Gene Expression, Neoplastic

Related Publications

Fredrik Edfors, and Tove Boström, and Björn Forsström, and Marlis Zeiler, and Henrik Johansson, and Emma Lundberg, and Sophia Hober, and Janne Lehtiö, and Matthias Mann, and Mathias Uhlen
January 1991, Journal of immunological methods,
Fredrik Edfors, and Tove Boström, and Björn Forsström, and Marlis Zeiler, and Henrik Johansson, and Emma Lundberg, and Sophia Hober, and Janne Lehtiö, and Matthias Mann, and Mathias Uhlen
April 2002, Analytical chemistry,
Fredrik Edfors, and Tove Boström, and Björn Forsström, and Marlis Zeiler, and Henrik Johansson, and Emma Lundberg, and Sophia Hober, and Janne Lehtiö, and Matthias Mann, and Mathias Uhlen
February 2013, Analytical biochemistry,
Fredrik Edfors, and Tove Boström, and Björn Forsström, and Marlis Zeiler, and Henrik Johansson, and Emma Lundberg, and Sophia Hober, and Janne Lehtiö, and Matthias Mann, and Mathias Uhlen
October 1998, Biopharmaceutics & drug disposition,
Fredrik Edfors, and Tove Boström, and Björn Forsström, and Marlis Zeiler, and Henrik Johansson, and Emma Lundberg, and Sophia Hober, and Janne Lehtiö, and Matthias Mann, and Mathias Uhlen
September 2015, Proteomics,
Fredrik Edfors, and Tove Boström, and Björn Forsström, and Marlis Zeiler, and Henrik Johansson, and Emma Lundberg, and Sophia Hober, and Janne Lehtiö, and Matthias Mann, and Mathias Uhlen
August 1987, Journal of immunological methods,
Fredrik Edfors, and Tove Boström, and Björn Forsström, and Marlis Zeiler, and Henrik Johansson, and Emma Lundberg, and Sophia Hober, and Janne Lehtiö, and Matthias Mann, and Mathias Uhlen
December 2005, Analytical chemistry,
Fredrik Edfors, and Tove Boström, and Björn Forsström, and Marlis Zeiler, and Henrik Johansson, and Emma Lundberg, and Sophia Hober, and Janne Lehtiö, and Matthias Mann, and Mathias Uhlen
September 2022, Analytical chemistry,
Fredrik Edfors, and Tove Boström, and Björn Forsström, and Marlis Zeiler, and Henrik Johansson, and Emma Lundberg, and Sophia Hober, and Janne Lehtiö, and Matthias Mann, and Mathias Uhlen
January 2015, mAbs,
Fredrik Edfors, and Tove Boström, and Björn Forsström, and Marlis Zeiler, and Henrik Johansson, and Emma Lundberg, and Sophia Hober, and Janne Lehtiö, and Matthias Mann, and Mathias Uhlen
March 2010, Analytical chemistry,
Copied contents to your clipboard!